PLYMOUTH MEETING, Pa.,
Sept. 30, 2014 /PRNewswire/
-- Inovio Pharmaceuticals, Inc. (NASDAQ: INO) today announced
the appointment of Jennifer Laux as
Vice President, Commercial. In this position she will be charged
with the development of Inovio's commercialization strategy for its
growing portfolio of oncology and infectious disease DNA
immunotherapies. As Inovio advances its lead program into phase
III, Ms. Laux will direct commercial development for the company's
immunotherapies to treat HPV and the pre-cancers and cancers caused
by this infection.
Ms. Laux has over 20 years of experience in life sciences,
strategic consulting, and marketing, including leadership of
multi-billion dollar franchises. She recently served as Vice
President, Cardiovascular Marketing, at Boehringer Ingelheim. Ms.
Laux spent most of her career at Merck & Co., where she led US
marketing for the cardiovascular franchise and held marketing
leadership positions in Merck's oncology, specialty, and women's
health businesses. Her international experience includes marketing
for Procter & Gamble in Brussels and Elizabeth
Arden in Paris. Ms. Laux
holds a MBA in Marketing from The Wharton School, a MA in
International Studies from the University of
Pennsylvania, and a BA in International Relations from
Georgetown University.
Dr. J. Joseph Kim, Inovio's
President and CEO, said: "I'm pleased to welcome Jennifer to Inovio
as we advance into phase III and invest in maximizing the
commercial opportunity for our innovative pipeline of DNA
immunotherapies. Jennifer's significant experience in building
successful global franchises coupled with her strong leadership
will be a driving force in bringing our immunotherapies to patients
who most need them and in growing the company."
About Inovio Pharmaceuticals, Inc.
Inovio is revolutionizing the fight against cancer and
infectious diseases. Our immunotherapies uniquely activate
best-in-class immune responses to prevent and treat disease, and
have shown clinically significant efficacy with a favorable safety
profile. With an expanding portfolio of cancer immunotherapies and
clinical studies, the company is advancing a growing product
pipeline. Partners and collaborators include Roche, the
University of Pennsylvania, NIH, HIV
Vaccines Trial Network, National Cancer Institute, U.S. Military
HIV Research Program, US Dept. of Homeland Security, and
University of Manitoba. For more
information, visit www.inovio.com.
This press release contains certain forward-looking
statements relating to our business, including our plans to develop
electroporation-based drug and gene delivery technologies and DNA
vaccines and our capital resources. Actual events or results may
differ from the expectations set forth herein as a result of a
number of factors, including uncertainties inherent in pre-clinical
studies, clinical trials and product development programs
(including, but not limited to, the fact that pre-clinical and
clinical results referenced in this release may not be indicative
of results achievable in other trials or for other indications,
that the studies or trials may not be successful or achieve the
results desired, including safety and efficacy for VGX-3100, that
pre-clinical studies and clinical trials may not commence or be
completed in the time periods anticipated, that results from one
study may not necessarily be reflected or supported by the results
of other similar studies and that results from an animal study may
not be indicative of results achievable in human studies), the
availability of funding to support continuing research and studies
in an effort to prove safety and efficacy of electroporation
technology as a delivery mechanism or develop viable DNA vaccines,
our ability to support our broad pipeline of SynCon®
active immune therapy and vaccine products, the adequacy of our
capital resources, the availability or potential availability of
alternative therapies or treatments for the conditions targeted by
the company or its collaborators, including alternatives that may
be more efficacious or cost-effective than any therapy or treatment
that the company and its collaborators hope to develop, evaluation
of potential opportunities, issues involving product liability,
issues involving patents and whether they or licenses to them will
provide the company with meaningful protection from others using
the covered technologies, whether such proprietary rights are
enforceable or defensible or infringe or allegedly infringe on
rights of others or can withstand claims of invalidity and whether
the company can finance or devote other significant resources that
may be necessary to prosecute, protect or defend them, the level of
corporate expenditures, assessments of the company's technology by
potential corporate or other partners or collaborators, capital
market conditions, the impact of government healthcare proposals
and other factors set forth in our Annual Report on Form 10-K
for the year ended December 31, 2013, our Form 10-Q for the
quarter ended June 30, 2014, and
other regulatory filings from time to time. There can be no
assurance that any product in Inovio's pipeline will be
successfully developed or manufactured, that final results of
clinical studies will be supportive of regulatory approvals
required to market licensed products, or that any of the
forward-looking information provided herein will be proven
accurate.
CONTACTS:
|
|
Investors:
|
Bernie Hertel, Inovio
Pharmaceuticals, 858-410-3101, bhertel@inovio.com
|
Media:
|
Jeff Richardson,
Inovio Pharmaceuticals, 267-440-4211,
jrichardson@inovio.com
|
Logo -
http://photos.prnewswire.com/prnh/20131118/LA18202LOGO
SOURCE Inovio Pharmaceuticals, Inc.